Product image

Rectamid is a polyacrylamide hydrogel being developed as a minimally invasive, effective and safe
treatment for faecal incontinence.

Based upon Contura’s proprietary hydrogel technology, Rectamid seeks to address the need for a
treatment that is more effective than conservative management, but much less invasive than
complex and expensive surgical procedures such as sphincter reconstruction or
sacral nerve stimulation.

Product image

Bulkamid is being investigated for use in male urinary incontinence following radical
prostatectomy surgery for prostate cancer.

Despite improvements in surgical techniques the risk of post prostatectomy
incontinence (PPI) remains significant. The prevalence of PPI ranges
from 5 to 48%. PPI continues to have a major negative impact on patients’ quality of lives
after surgery for prostate cancer. A minimally invasive bulking procedure with minimal
morbidity appeals to both patients and clinicians.